Skip NavigationSkip to Content
 
 


     The NCI BRB Program Staff provide oversight of the Biopharmaceutical Development Program (BDP) at the National Cancer Institute Frederick campus (NCI-Frederick). The BDP produces a variety of biopharmaceuticals under current Good Manufacturing Practices (cGMP) for Phase I/II human clinical trials or advanced preclinical animal testing. The BDP is operated under contract by Scientific Applications International Corporation (SAIC) Frederick, which provides operations and technical support to the FCRDC.


Recombineering Reagents can be ordered on-line: These reagents are no longer available: